| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 07/31/2002 | EP1226136A2 Tyrosine kinase inhibitors |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1226110A1 Bicyclic amino acids as pharmaceutical agents |
| 07/31/2002 | EP1226109A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1226104A1 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/31/2002 | EP1225915A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 07/31/2002 | EP1225903A2 Aminoalkylenephosphonates for treatment of bone disorders |
| 07/31/2002 | EP1225894A1 Fab i inhibitors |
| 07/31/2002 | CN1361792A Cyclic peptide derivatives as inhibitors of integrin alpha/beta |
| 07/31/2002 | CN1361783A Thiazoloderivatives and pharmaceutical compositions containing them |
| 07/31/2002 | CN1361782A Substituted imidazothiazoles as antidepressant agents |
| 07/31/2002 | CN1361779A New compounds |
| 07/31/2002 | CN1361775A Novel diphenyl-piperidine derivate |
| 07/31/2002 | CN1361773A Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/31/2002 | CN1361767A 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 07/31/2002 | CN1361763A Aminobenzophenones as inhibitors of IL-1 beta and TNF_alpha |
| 07/31/2002 | CN1361690A Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 07/31/2002 | CN1361687A Phosphate transport inhibitors |
| 07/31/2002 | CN1360919A Nanometer Guxian medicine and its prepn |
| 07/31/2002 | CN1360913A Nanometer Xiaojing medicine and its prepn |
| 07/31/2002 | CN1360912A Nanometer spur treating medicine and its prepn |
| 07/31/2002 | CN1360896A Medicine for treating cervical vertebra disease |
| 07/31/2002 | CN1088361C Combined use of diclofenac and tribenoside to treat osteoarthritis |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426413 Inhibitors of caspases |
| 07/30/2002 | US6426402 Respiratory system disorders; rheumatic diseases |
| 07/30/2002 | US6426359 Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists |
| 07/30/2002 | US6426353 α v integrin receptor antagonists |
| 07/30/2002 | US6426345 Phosphodiesterase inhibitors; antiinflammatory agents |
| 07/30/2002 | US6426332 Osteogenic protein is provided alone or dispersed in a biocompatible non-rigid, amorphous carrier having no defined surfaces |
| 07/30/2002 | US6426222 Incubation tissue cells in liquid nutrients |
| 07/30/2002 | US6426208 Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
| 07/30/2002 | US6426100 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 07/30/2002 | CA2236021C Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities: process of making metho ds of using and compositions thereof |
| 07/30/2002 | CA2228997C Benzothiophene compounds |
| 07/30/2002 | CA2104461C Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same |
| 07/25/2002 | WO2002057795A2 Methods of diagnosis and treatment of osteoporosis |
| 07/25/2002 | WO2002057778A1 Screening assay for cotranslational translocation interfering compounds |
| 07/25/2002 | WO2002057454A2 Receptors and membrane-associated proteins |
| 07/25/2002 | WO2002057453A2 Polypetides and nucleic acids encoding same |
| 07/25/2002 | WO2002057452A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | WO2002057298A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | WO2002057284A1 New inhibitors against galectins |
| 07/25/2002 | WO2002057271A2 Thienopyrimidine-based inhibitors of the src family |
| 07/25/2002 | WO2002057265A1 Compounds substituted with bicyclic amino groups |
| 07/25/2002 | WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors |
| 07/25/2002 | WO2002057255A1 4- or 5-substituted pyrrole derivatives |
| 07/25/2002 | WO2002057242A2 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | WO2002057241A1 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES |
| 07/25/2002 | WO2002057230A1 Il-8 receptor antagonists |
| 07/25/2002 | WO2002057211A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | WO2002056897A2 Pharmaceutical for stimulating the regeneration of tissues |
| 07/25/2002 | WO2002056894A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent |
| 07/25/2002 | WO2002056877A1 Treatment of sleep disturbances |
| 07/25/2002 | WO2002056874A2 Lipid-based nitric oxide donors |
| 07/25/2002 | WO2002056873A2 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues |
| 07/25/2002 | WO2002056790A2 Delivery of therapeutic capable agents |
| 07/25/2002 | WO2002042268A3 Ep4 receptor selective agonists in the treatment of osteoporosis |
| 07/25/2002 | WO2002040041A3 Orally ingestible preparation of mistletoe lectins and method |
| 07/25/2002 | WO2002039988A3 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 07/25/2002 | WO2002033085A9 Wisp polypeptides and therapeutical applications thereof |
| 07/25/2002 | WO2002032901A3 Bridged piperazine derivatives |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/25/2002 | WO2002030874A3 Aliphatic, cyclic amino carboxylic acids as integrin antagonists |
| 07/25/2002 | WO2002020615A3 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 07/25/2002 | WO2002018379A3 7-oxo pyridopyrimidines |
| 07/25/2002 | WO2002015886A3 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002015884A3 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002014320A3 Novel substituted diaryl azepine derivatives as integrin ligands |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2001094413A3 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 07/25/2002 | WO2001090091A8 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 07/25/2002 | WO2001088126A3 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 07/25/2002 | WO2001082919B1 Methods of and compounds for inhibiting calpains |
| 07/25/2002 | WO2001080894A3 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| 07/25/2002 | WO2001078701A3 Method and compositions for preventing hormone induced adverse effects |
| 07/25/2002 | WO2001070798A3 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 07/25/2002 | WO2001039795A9 Attenuation of fibroblast proliferation |
| 07/25/2002 | WO2001034201A9 Methods for inhibiting neurofibromatosis type 1 (nf1) |
| 07/25/2002 | WO2001007056A9 Method of promoting bone growth with hyaluronic acid and growth factors |
| 07/25/2002 | WO2001002567A9 16405 receptor, a g-protein coupled receptor |
| 07/25/2002 | WO2001000812A9 22012, a novel human carboxypeptidase |
| 07/25/2002 | US20020099216 Compounds useful in therapy |
| 07/25/2002 | US20020099209 Dihydrostilbene alkanoic acid derivatives |
| 07/25/2002 | US20020099207 Has activity as an antagonist to neurokinin 1 receptors; for therapy of benign prostatic hyperplasia (BPH) |
| 07/25/2002 | US20020099190 Nuclelotide sequences coding protein for use in the treatment and prevention of atherosclerosis, osteoporosis and nervous system disorders |
| 07/25/2002 | US20020099096 Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer |
| 07/25/2002 | US20020099071 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia |
| 07/25/2002 | US20020099068 I kappa B kinase inhibitors for treating various disorders including arthritis |
| 07/25/2002 | US20020099010 Neurogenic compositions and methods |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | US20020098524 Screening peptide library for preferential proteins; obtain library, incubate with antitarget, separate unbound peptides, incubate unbound peptides with target binding protein, detect bound peptide complexes |
| 07/25/2002 | US20020098206 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | CA2443080A1 Lipid-based nitric oxide donors |
| 07/25/2002 | CA2435363A1 New inhibitors against galectins |
| 07/25/2002 | CA2435260A1 Receptors and membrane-associated proteins |
| 07/25/2002 | CA2435248A1 Drug composition for the promotion of tissue regeneration |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434866A1 Screening assay for cotranslational translocation interfering compounds |